Kamyar Kalantar-Zadeh M.D. to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Dose-Response Relationship, Drug.
Connection Strength
0.677
-
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
Score: 0.158
-
Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population. Am J Nephrol. 2019; 49(2):133-142.
Score: 0.151
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
Score: 0.097
-
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009 May; 53(5):823-34.
Score: 0.076
-
Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008 Oct; 52(4):727-36.
Score: 0.073
-
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1769-76.
Score: 0.073
-
Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med. 2018 03; 283(3):314-327.
Score: 0.035
-
Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial. 2004 Sep-Oct; 17(5):336-41.
Score: 0.014